The insulin/IGF binding protein-1 (IGFBP-1) axis is important in coordinating insulin-and IGF-mediated regulation of glucose metabolism and glycemia. Dysregulation of the axis may play a role in the pathophysiology of disorders of insulin deficiency and resistance. We have investigated this hypothesis by generating transgenic mice that overexpress hIGFBP-1. To study the axis in its true physiological context, we used a human (h) IGFBP-1 cosmid clone so that transgene expression is responsive to normal hormonal stimuli. hIGFBP-1 mRNA is expressed in a tissue-specific fashion, and measurement of serum protein levels by specific immunoassay indicates normal physiological regulation in response to fasting/feeding and appropriate post-translational modification as indicated by the detection of phosphorylated and nonphosphorylated isoforms of the protein. The hypoglycemic response to exogenous IGF-I is attenuated in transgenic mice. Transgenic mice exhibit an enhanced insulin secretory response to a glucose challenge, although basal and stimulated blood glucose levels are similar to controls. There is a sexual dimorphism in phenotypic expression: male transgenic mice had higher stimulated glucose and insulin levels than did females. Tr a n s g e n i c mice exhibit fasting hyperglycemia and hyperinsulinemia and glucose intolerance in later life, indicating an age-related decline in glucocompetence. These findings demonstrate the importance of the normal inverse relationship between serum insulin and IGFBP-1 levels in glucoregulation and that sustained dysregulation of the insulin/IGF-I/IGFBP-1 axis is associated with impaired glucose tolerance and abnormalities of insulin action. D i a b e t e s 4 9 :4 5 7-465, 2000
T
he IGFs (IGF-I and -II) have insulin-like actions on glucose metabolism in vivo, stimulating peripheral glucose uptake and utilization and reducing hepatic glucose production (1). These observations have led to speculation that the IGFs play a role in regulating carbohydrate metabolism and glycemia. The actions of the IGFs are modulated by the IGF binding proteins (IGFBPs), a family of high-affinity binding proteins that determine IGF bioavailability (2). One of the major functions of serum IGFBPs is regulation of the hypoglycemic potential of circulating IGFs, which are ~1,000-fold greater than insulin levels (3). IGFBP-1 is believed to play an important role in the acute regulation of serum free IGFs.
Insulin has multiple reciprocal interactions with the IGFs and their binding proteins. Insulin is a positive regulator of IGF-I synthesis in vivo and in vitro, acting at the level of hepatic gene transcription (4,5). In vivo studies of IGF-I administration have consistently shown an inhibitory effect on insulin secretion (6,7). Furthermore, IGF-I increases tissue sensitivity to insulin in patients with type 1 or type 2 diabetes (8,9). Serum IGFBP-1 levels fluctuate in response to nutritional status, largely as a result of negative regulation of hepatic IGFBP-1 gene expression by insulin (10,11). Epinephrine, glucagon, and corticosteroids are positive physiological regulators of IGFBP-1, although their effects are secondary to the inhibitory action of insulin. The hormonal regulation of IGFBP-1 synthesis is characteristic of counterregulatory hormones, leading to suggestions of a possible role in glucose counterregulation (12).
Dysregulation of the insulin/IGFBP-1 axis is a consistent feature of the human disease states of insulin deficiency and resistance. IGFBP-1 levels are elevated in type 1 diabetic patients and in some forms of acquired insulin resistance, such as type 2 diabetes (13,14). The elevated IGFBP-1 levels in these disease states reflect the reduced inhibitory effect of insulin on IGFBP-1 synthesis. The increase in IGFBP-1 levels may not be merely a consequence of insulin defic i e n c y / r e s i stance but might play a role in the pathophysiology of these conditions by virtue of its inhibitory effects on IGF activity. Some of the metabolic derangements in type 1 diabetic patients may be due to attenuation of the insulin-like actions of the IGFs (15) . Furthermore, it has been suggested that increased levels of IGF inhibitory IGFBPs may play a role in growth impairment in prepubertal children with poorly con-trolled type 1 diabetes and also in late-onset complications of t y p e 1 diabetes, such as retinopathy and nephropathy (16) .
To explore the role of the insulin/IGFBP-1 axis, we have experimentally manipulated the axis so that the normal inverse relationship between insulin and IGFBP-1 is disturbed. This has been achieved by overexpressing human (h) IGFBP-1 in transgenic mice. A transgenic model of IGFBP-1 overexpression has been previously generated, but the use of a heterologous promoter to control transgene expression means that its usefulness in elucidating the physiological function of the insulin/IGFBP-1 axis is limited (17) . We have improved on this model by developing transgenic mice using a cosmid clone encompassing the entire hIGFBP-1 s t r u c t u r a l gene and its regulatory sequences that is responsive to normal hormonal stimuli, thereby allowing us to study the axis in its true physiological context.
RESEARCH DESIGN AND METHODS
Generation of transgenic mice. A cosmid clone, chBP1:2, encompassing the hIGFBP-1 structural gene, has been reported previously (18) . A 35-kb N o tI fragment of chBP1:2 was gel purified, quantitated, and then diluted to give a final concentration of 1-2 µg/ml. The DNA was microinjected into the male pronucleus of fertilized C57Bl/CBA oocytes. Transgenic mice were initially identified by Southern blot analysis of DNA isolated from tail biopsies taken at weaning. E c oR I digests of mouse DNA were transferred to Hybond N + hybridization membrane by standard procedures (19) and probed with a [ -3 2 P]dCTP-labeled hIGFBP-1 cDNA (20) . Founder animals positive for the transgene were mated with CBA/Ca mice to produce heterozygous transgenic F 1 animals. F 1 and F 2 transgenic males were bred back to CBA/Ca females to yield F 3 animals, which were used in these studies. Control mice used in the experiments described were age-and sexmatched nontransgenic littermates. RNA isolation and analysis. Total RNA was extracted from frozen tissue using RNAzolB according to the manufacturer's instructions (Biogenesis, Poole, U.K.). For Northern analysis, 20 µg of total RNA was electrophoresed on a 1.2% denaturing formaldehyde gel, transferred to Hybond N + , and probed with a [ -3 2 P]dCTP-labeled hIGFBP-1 cDNA. Gene expression was also analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Total RNA (2.5 µg) was reverse-transcribed using Superscript II and random hexamers following the m a n u f a c t u r e r 's guidelines (Life Technologies, Paisley, U.K.). cDNA was amplifie d by PCR with the primer pair HBP1 F (5 -A A C C T C T G C A C G C C C T C A C C -3 ) and HBP1 R (5 A G G G ATCCTCT TCCCAT T C C A A G G G TA G A C -3 ), which specific a l l y amplify hIGFBP-1 cDNA. Competitive RT-P C R Construction of the internal cRNA standard for competitive RT-PCR. T h e internal cRNA standard for quantitative RT-PCR was prepared by amplifying human liver cDNA with the primer pair CPT7HBP1
The internal competitor is designed to be amplified by the same primer pair as the target but it generates a product that is 52 bp smaller that can be distinguished from the target by agarose gel electrophoresis. The amplified product was transcribed in vitro using T7 polymerase (Stratagene, Cambridge, U.K.), and the transcript was run on a 1.5% denaturing formaldehyde gel to confirm its size and integrity and quantitated by spectrophotometry. cDNA synthesis and PCR amplific a t i o n . Total liver RNA was isolated from fasted and ad libitum-fed transgenic mice. An equal mass of RNA from individual transgenic animals in each group was pooled, and 2.5 µg of it was reverse transcribed in the presence of twofold dilutions of the internal standard cRNA. cDNA was amplified using the primer pair HBP1 F and HBP1 R. PCR products were analyzed by electrophoresis on 2% agarose gels. The band intensity was determined by densitometry (GDS 7000 and Gel Pro Analyser software; UVP, Cambridge, U.K.), and the mean ratio of the intensity of the target (A t ) to competitor (A c )was calculated for each amount of the internal standard added. Western ligand blot analysis. Samples of sera from transgenic and wild-type animals containing an equal mass of protein were diluted with sample buffer and denatured at 100°C for 5 min before electrophoresis on a 12% SDS-polyacrylamide gel. The gel was electroblotted to nitrocellulose (Hybond C; Amersham, Amersham, U.K.). After incubation with 1 2 5 I-labeled IGF-I and -II, the filter was washed to remove unbound ligand, and the IGFBPs were visualized by autoradiography. Assays for hIGFBP-1, insulin, and IGF-1. Total and nonphosphorylated hIGFBP-1 in sera of transgenic mice was measured by immunoradiometric assay (IRMA) (Diagnostic Systems Laboratories, We b s t e r, TX) (21) . Both assays show absolute specificity for hIGFBP-1. Murine insulin and IGF-I were measured by radioimmunoassay (Biogenesis, Poole, U.K.). For comparison of fasting and nonfasting sera, samples were collected from overnight fasted mice. These mice were then allowed access to food for 4 h, after which a second sample was taken. Intraperitoneal glucose tolerance tests. Mice were fasted overnight before testing. Blood samples were collected before and 30 min after administration of an intraperitoneal injection of glucose (1 mg/g body weight in sterile saline). Samples for measurement of hIGFBP-1, insulin, and IGF-I were centrifuged for 10 min at 2,500 rpm, and the plasma was stored at -20°C. The time course of glucose uptake was determined by measurement of whole blood glucose before and 30, 60, and 120 min after a similar glucose challenge. Whole blood glucose was determined in duplicate at each time point using a a portable blood glucose analyzer (Hemocue, Sheffield, U.K.) IGF-I administration. Recombinant human IGF-I (0.2 µg/g body weight) was administered subcutaneously to overnight fasted mice, and whole blood glucose was measured as described above. Statistical analysis. Results are presented as means ± SE. Comparisons were made by analysis of variance or Student's t test after log normalization of nonparametric data. Where P < 0.05, analysis of variance was completed using F i s h e r 's least significant difference test. Correlations were made by simple regression analysis.
R E S U LT S
Generation of hIGFBP-1 transgenic mice. Three of seven mice (designated c1:2-1, c1:2-2, and c1:2-11) born after microinjection of the N otI fragment of chBP1:2 were positive for the transgene. Southern blot analysis of tail DNA from all three founders indicates that the cosmid integrated without any gross rearrangements and was present in multiple copies ( F i g . 1B). The copy number was estimated to range from 8 to 20 by slot blot analysis in the three lines (data not shown). . hIGFBP-1 mRNA was most abundant in the liver, followed by the kidney and uterus, with much lower levels in heart, small intestine, spleen, and brain ( Fig. 2A) . The sites of expression and relative abundance of hIGFBP-1 mRNA in tissues of transgenic mice are very similar to those of the endogenous murine gene in nontransgenic mice (Fig. 2B ). The liver transcript size was estimated to be 1.6 kb by Northern blot analysis, which is identical in size to the transcript size in human liver ( Fig. 2C ; data shown only for line c1:2-2). Serum IGFBP-1 levels in transgenic mice. Total IGFBP-1 levels (i.e., murine plus hIGFBP-1) in sera of transgenic mice were assessed by Western ligand blot analysis. Figure 3 shows a Western ligand blot of fasting sera from transgenic mice and wild-type controls. In sera of transgenic mice, there is a marked increase in the abundance of a 30-kDa IGFBP corresponding to IGFBP-1. Estimation of serum hIGFBP-1. Total and nonphosphorylated hIGFBP-1 were quantitated in sera of transgenic mice using specific IRMAs. The mean fasting total hIGFBP-1 in sera of transgenic mice was 174.1 ± 29.7 µg/l (mean nonphosphorylated hIGFBP-1 was 99.1 ± 32 µg/l). hIGFBP-1 was undetectable in sera of wild-type controls, confirming the s p e c i ficity of both assays. Physiological regulation of hIGFBP-1. To determine whether hIGFBP-1 is responsive to normal physiological stimuli in transgenic mice, we compared hepatic gene expression and circulating levels of hIGFBP-1 in relation to nutritional status. Matched fasting and nonfasting sera from transgenic mice were assayed for total hIGFBP-1, nonphosphorylated hIGFBP-1, and insulin (Ta b l e 1 and Fig. 4 ). The nonfasting hIGFBP-1 level was reduced by 81% compared with fasting levels. The normal inverse relationship between insulin and IGFBP-1 is maintained in transgenic mice ( F i g . 4B). Figure 5 shows the results of competitive RT-P C R analysis of liver RNA from fasted and fed mice. There is a 1 2-fold reduction in expression levels in the nonfasting state, accounting for the decrease in the serum level of the protein.
Response to IGF-I administration. The hypoglycemic response to exogenous IGF-I is attenuated in transgenic mice . Blood glucose levels in transgenic mice were higher at all time points after the glucose challenge compared with controls, although this was only significant at 60 and 120 min. There is a marked sexual dimorphism in the response to IGF-I. In wild-type males, there is an increase in blood glucose levels at 30 min and then a rapid decline. This initial increase in blood glucose is abolished in male transgenic mice. In contrast, both wild-type and transgenic females show a rapid fall in blood glucose levels, the fall being more pronounced in wild-type animals. Glucoregulation in transgenic mice. Comparison of fasting and nonfasting blood glucose and insulin levels in transgenic and wild-type littermates at age 16-20 weeks indicated no significant differences between groups. However, there was a marked difference in the response to an intraperitoneal glucose challenge in transgenic mice (Ta b l e 2 and F i g . 7). The 30-min insulin levels were 2.5-fold greater in transgenic males (37% increase in females), although blood glucose levels were similar to controls. Fasting insulin and glucose levels in transgenic males did not differ signific a n t l y from sex-matched controls. The glucose/insulin ratio is significantly lower in transgenic males after a glucose challenge. Transgenic males had significantly higher 30-min glucose and insulin levels compared with females. Analysis of data from control mice indicates no similar differences. Although the fasting and 30-min hIGFBP-1 levels were simi l a r, there was a significant increase in the relative proportion of the nonphosphorylated isoform in sera of transgenic mice ( Ta b l e 2). IGF-I levels did not differ between groups in either basal or stimulated sera (Fig. 7B) . Transgenic mice have normal glucose tolerance based on blood glucose levels 30, 60, and 120 min after a glucose challenge (data not shown). Age-related changes in glucoregulation. We measured fasting blood glucose, total hIGFBP-1, and insulin and performed intraperitoneal glucose tolerance tests at age 40-44 weeks to determine if sustained overexpression of hIGFBP-1 in transgenic mice is associated with more profound abnormalities of glucoregulation. There was a marked deterioration in glucocompetence with age, as demonstrated by increased fasting blood glucose and insulin levels in transgenic male mice (Fig. 8A) . Fasting hIGFBP-1 levels were reduced, r e flecting the relative hyperinsulinemia. Intraperitoneal glucose tolerance tests indicated a marked impairment in the ability to dispose of a glucose load compared with age-and sex-matched controls (Fig. 8B) . Fasting blood glucose and insulin levels were moderately elevated in female transgenic mice compared with sex-matched controls, but the data did not reach statistical significance. This was also true of glucose 
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tolerance, which showed a mild but statistically insignific a n t i m p a i r m e n t . Growth of hIGFBP-1 transgenic mice. The body weights of transgenic and control mice were measured to examine possible effects of hIGFBP-1 overexpression on postnatal growth (Fig. 9) . Transgenic mice were ~10% lighter than wildtype littermates at weaning, but by 8 weeks of age this defic i t had narrowed such that body weights were essentially identical. The parity in body weight was maintained until the last recorded measurements at 12-16 weeks. A signific a n t inverse correlation was observed between fasting serum hIGFBP-1 and body weight and IGF-I levels in adult transgenic mice (Fig. 9B) . Measurements of serum IGF-I levels correlate well with body weights and sex in both groups, but no significant differences were observed between transgenic and control animals.
D I S C U S S I O N
This study was undertaken to investigate the physiological s i g n i ficance of the inverse relationship between insulin and IGFBP-1 and its role in regulating glucose metabolism and glycemia. The role of IGFBP-1 in the acute regulation of serum free IGFs and the manner of its regulation by insulin and contra-insulin hormones, as well as the reciprocal relationship between insulin and IGF-I, are consistent with a model whereby the insulin/IGF-I/IGFBP-1 axis coordinates the metabolic and hypoglycemic activities of insulin and the IGFs in relation to fuel supply. We have developed transgenic mice that overexpress hIGFBP-1 to investigate this hypothesis. The transgene is a human cosmid clone encompassing the entire structural gene and all the c i s acting sequences necessary to direct appropriate tissue-specific and regulated gene expression. This approach avoids many of the problems associated with the use of heterologous promoters, such as atypical expression sites and low levels of expression. More importantly, the use of a constitutively active promoter would not provide insights into the changing nature of the axis in response to nutritional status. An important advantage of using the human gene is that although the human protein is fully compatible with the rodent IGF/IGFBP system, it is sufficiently distinct to allow us to distinguish it from the murine homologue at the mRNA and protein level. The availability of reagents for the detection of specific isoforms of hIGFBP-1 allows analysis of the phosphorylation status of the protein.
The tissue distribution of hIGFBP-1 mRNA in transgenic mice is more similar to the human than the murine pattern. In transgenic mice, renal hIGFBP-1 expression is low compared with the liver; but in wild-type mice, endogenous IGFBP-1 mRNA is equally abundant in the liver and the kidney (22) . Serum levels of hIGFBP-1 in transgenic mice are in the pathophysiological range. 
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mal human serum are in the range of 50-80 ng/ml, falling to < 1 0 ng/ml in the nonfasting state.
hIGFBP-1 levels in sera of transgenic mice vary in response to nutritional status, and the normal inverse relationship between hIGFBP-1 and insulin levels is evident. Hepatic hIGFBP-1 mRNA levels are reduced in the nonfasting state consistent with the inhibitory effect of insulin on hepatic IGFBP-1 gene transcription. However, the relationship between insulin and hIGFBP-1 levels is not absolute. It can be seen that even in the nonfasting state when insulin levels are maximal, hIGFBP-1 levels in the circulation, although reduced compared with fasting levels, are considerably higher than would be expected. Therefore, regulated overexpression of hIGFBP-1 in transgenic mice is a model of reduced sensitivity of IGFBP-1 to insulin regulation. This is the only transgenic model of IGFBP-1 overexpression to show appropriate post-translational modification of the protein. IGFBP-1 has both inhibitory and stimulatory effects on IGF Data are means ± SE for the indicated number of animals. Matched serum samples were collected before and 30 min after an intraperitoneal glucose challenge. Statistically significant differences between transgenic and age-matched control animals in stimulated sera and between the nonphosphorylated/total hIGFBP-1 ratio in basal and stimulated sera of transgenic mice are shown. *P < 0.05; †P < 0.02. 
activity in vitro (23, 24) . This differential action appears to be due to the phosphorylation status of the protein, which can vary depending on its origin. Phosphorylated IGFBP-1 has a threeto fivefold greater IGF binding affinity than the nonphosphorylated protein.
In vivo regulation of IGFBP-1 phosphorylation has not been convincingly demonstrated, and its physiological s i g n i ficance remains unclear. However, the striking differences in the phosphorylation status of IGFBP-1 in different fetomaternal compartments argues in favor of it having an in vivo role in modulating IGFBP-1 function, at least in fetal growth and development (25) . IGFBP-1 in normal human serum is present predominantly as a single, highly phosphorylated species (>95%). The proportion of phosphorylated hIGFBP-1 in sera of transgenic mice is significantly lower (60-70%). This may be due to the fact that murine species lack hepatic protein kinases with the appropriate substrate specificity to phosphorylate hIGFBP-1 on the serine residues (serine 98 and 169) that are not con- phorylated hIGFBP-1 after a glucose challenge is intriguing, particularly when total hIGFBP-1 levels remain unchanged. In physiological terms, there is a compelling rationale for such a phenomenon. Nonphosphorylated IGFBP-1 would be less inhibitory to the insulin-like actions of the IGFs at a time when this activity needs to be maximized, i.e., in response to a glucose challenge. Insulin itself, or perhaps glucose, may stimulate hepatocytes to alter the pattern of protein phosphorylation. Hormonal regulation of IGFBP-1 phosphorylation has been reported in humans, but the physiological significance and mechanisms involved require clarification (26) . We have demonstrated specific abnormalities of glucoregulation in hIGFBP-1 mice. At age 16-20 weeks, hIGFBP-1 transgenic mice have normal fasting glucose and insulin levels. Even after a glucose challenge, blood glucose levels in transgenic mice are similar to controls, albeit at the expense of a twofold increase in insulin secretion. The coordinated actions of insulin on glucose transport and IGFBP-1 expression enhance the ability to respond to a glucose challenge when insulin levels are high, and the insulin-like activity of the IGFs can be expressed because of the insulin-mediated suppression of IGFBP-1. The finding of normal fasting blood glucose in transgenic mice and the observation that insulin secretion is only perturbed following a glucose challenge are consistent with this analysis.
Our hypothesis is that the insulin/IGFBP-1 axis is important in coordinating the metabolic and hypoglycemic activities of insulin and the IGFs and that dysregulation of the axis may give rise to abnormalities of insulin action, leading to insulin resistance and ultimately glucose intolerance. The rationale is that if insulin-mediated reduction of IGFBP-1 levels in the nonfasting state is not absolute, then serum IGFBP-1 has the potential to attenuate the hypoglycemic actions of the IGFs. In our view, this would precipitate nonfasting hyperinsulinemia by a number of mechanisms acting in synergy and which are related to a reduction in IGF bioavailabilty. Attenuation of the hypoglycemic actions of the IGFs by IGFBP-1 may elicit a compensatory increase in insulin secretion to maintain normal blood glucose levels. The reduced inhibitory action of the IGFs on insulin secretion would have a similar outcome. Because IGF-I is reported to increase insulin sensitivity in humans and rodents, the reduction in IGF bioactivity could lead to desensitization of insulin-responsive tissues, namely skeletal muscle. The increase in insulin secretion after a glucose challenge in hIGFBP-1 mice is of the order of 2.5-fold greater than in controls. The cumulative effect of this level of insulin hypersecretion over a long period of time would inevitably lead to a decrease in tissue sensitivity to insulin, stimulating yet further insulin secretion. This prediction is borne out in hIGFBP-1 mice with the onset of fasting hyperglycemia and hyperinsulinemia and glucose intolerance with advancing age. The progression from normoglycemia and hyperinsulinemia to overt fasting hyperglycemia, hyperinsulinemia, and glucose intolerance in hIGFBP-1 is similar to some animal models of type 2 diabetes.
Abnormalities of hepatic insulin sensitivity offer the most plausible scenario by which the insulin/IGFBP-1 axis may be perturbed. Defects in insulin action at the receptor or postreceptor level could attenuate the inhibitory action of insulin on IGFBP-1 gene transcription. Liver-enriched transcription factors such as the hepatocyte nuclear factor (HNF) family (HNF-1 to -4) are important in regulating the expression of genes such as IGFBP-1 that are highly expressed in the liver. R e c e n t l y, mutations in the HNF-1 and HNF-4 genes have been reported in patients with maturity-onset diabetes of the young (MODY), a rare form of type 2 diabetes (27, 28) . The role of the three known MODY genes in susceptibility to the more common late-onset form of type 2 diabetes remains uncertain. F i n a l l y, the phenomenon of "metabolic programming" is thought to underlie the epidemiological association between low birth weight and the incidence of type 2 diabetes in adult life (29) . It has been suggested that abnormalities of the insulin/IGFBP-1 axis may be programmed in utero in response to fetal undernutrition (30) . Circulating levels of IGFBP-1 and insulin are increased in fetuses with intrauterine growth restriction (31) , and several studies have shown that children who were small at birth have impaired glucose tolerance and insulin resistance in adult life (32, 33) .
Our findings are distinct from those reported in IGFBP-1 transgenic mice in which gene expression is regulated by the mouse phophoglycerate kinase (PGK) promoter (PGKrIGFBP-1). PGK-rIGFBP-1 mice exhibit basal and stimulated hyperglycemia and hyperinsulinemia and have impaired glucose tolerance from an early age (34) . At a comparable age, hIGFBP-1 mice have normal fasting and nonfasting blood glucose and insulin but exhibit hyperinsulinemia after a glucose challenge. The increase in insulin secretion in response to a glucose challenge in PGK-rIGFBP-1 mice is less than that of wild-type controls (1.6-vs. 3.99-fold increase over basal levels). The glucose/insulin ratio falls in hIGFBP-1 mice but increases in PGK-rIGFBP-1 mice after a glucose load. Another divergence in the phenotypes is the age-related decline in serum insulin levels in PGK-rIGFBP-1 mice, in contrast to the increase in insulin secretion in hIGFBP-1 mice between the ages of 4 and 10 months.
hIGFBP-1 transgenic mice have a moderate degree of growth restriction in early postnatal life before weaning, but there appears to be "catch-up growth," as the weight difference is no longer evident by 8 weeks of age. In contrast, the growth restriction in PGK-IGFBP-1 transgenic mice follows a different pattern. The growth trajectories of transgenic and wild-type mice diverge early in postnatal life and continue into adult life with no evidence of catch-up growth.
Given the similarity in the weights of adult hIGFBP-1 transgenic and wild-type littermates, the negative correlation between hIGFBP-1 levels and IGF-I levels and body weight in adult transgenic mice is surprising. Gross body weight is a crude measurement of growth, because it does not distinguish between linear and nonlinear growth, i.e., increased adiposi t y. Therefore, it is possible that a reduction in linear growth may be counterbalanced by an increase in adiposity with no net change in body weight. We have demonstrated specific defects in glucoregulation in hIGFBP-1 mice that are consistent with insulin resistance. The conventional view that obesity predisposes to the development of insulin resistance is well established, but an alternative, though not mutually exclusive hypothesis, is that resistance to insulin-mediated glucose disposal in muscle can result in an increase in adiposity (35) . Altered nutrient partitioning, leading to an increase in triglyceride synthesis and storage in adipose tissue, may be a consequence of diminished muscle glucose utilization. In addition, the hyperinsulinemia associated with insulin resistance may have direct anabolic actions on adipose tissue. Further investigation of lean body mass and adiposity in hIGFBP-1 transgenic mice will be necessary to determine if this applies.
The observation of early postnatal growth restriction suggests that its origins may be in utero life. Increased hepatic expression and circulating IGFBP-1 levels are a consistent finding in animal models of intrauterine growth restriction and in human studies of small-for-gestational-age fetuses. We have recently demonstrated hepatic transgene expression in hIGFBP-1 transgenic conceptuses (P.A.C., C.C. Pillai, J.P.M., unpublished o b s e r v a t i o n s ) .
In conclusion, we have generated transgenic mice that overexpress hIGFBP-1 as a model system to study the regulation and function of the insulin/IGF-I/IGFBP-1 axis in an in vivo physiological context. The analyses performed here c o n firm the fundamental importance of the normal inverse relationship between insulin and IGFBP-1 in glucoregulation. We present evidence that sustained dysregulation of the axis leads to profound abnormalities of glucose homeostasis that have some similarities to the pathophysiology of t y p e 2 diabetes.
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